Paper26817954
Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms.
Araki M and 12 others. Blood, 2016. Cited by 249 papers, by iCite.
Cite this record
ConductScience Library. Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms. Papers, record 26817954. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/26817954
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms.
- PubMed
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Calreticulin | Major topic |
| Hematologic Neoplasms | Major topic |
| Myeloproliferative Disorders | Major topic |
| Neoplasm Proteins | Major topic |
| Receptors, Thrombopoietin | Major topic |
| Cell Line, Tumor | |
| HEK293 Cells | |
| Humans | |
| Induced Pluripotent Stem Cells | |
| Janus Kinase 2 | |
| Phosphorylation | |
| Protein Structure, Tertiary | |
| Thrombopoiesis | |
| Thrombopoietin |
Source PubMed
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 26965919 | Mutant calreticulin: when a chaperone becomes intrusive. | https://conductscience.org/library/papers/26965919 |
Source PubMed
Cited by174
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 249 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42956057 | Molecular and functional analysis of calcium binding by a cancer-linked calreticulin mutant. | Elife | 2026 | https://conductscience.org/library/papers/42956057 | PubMed |
| 42919838 | How could calreticulin-targeting therapies change the myelofibrosis transplant paradigm? | Bone Marrow Transplant | 2026 | https://conductscience.org/library/papers/42919838 | PubMed |
| 42860554 | Haematopoietic Cells Deficient for Calreticulin or Expressing Its Oncogenic Variants Maintain Functional Antigen Presentation. | J Cell Mol Med | 2026 | https://conductscience.org/library/papers/42860554 | PubMed |
| 42792882 | The Roles of Genetic and Epigenetic Abnormalities in Essential Thrombocythemia. | Genes (Basel) | 2026 | https://conductscience.org/library/papers/42792882 | PubMed |
| 42786200 | Selective dependency of CALR-mutant myeloproliferative neoplasms on TYK2 signaling. | Leukemia | 2026 | https://conductscience.org/library/papers/42786200 | PubMed |
| 42745000 | Type 1 interferon perturbates clonal competition by reshaping human blood development. | Nat Genet | 2026 | https://conductscience.org/library/papers/42745000 | PubMed |
| 42689321 | Targeting Thrombopoietin/MPL Signaling to Mitigate JAK2V617F-Driven Cardiac Microvascular Disease. | Arterioscler Thromb Vasc Biol | 2026 | https://conductscience.org/library/papers/42689321 | PubMed |
| 42650032 | Inflammatory and Immune Microenvironment in Myeloproliferative Neoplasms: Pathogenic Mechanisms and Therapeutic Opportunities. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42650032 | PubMed |
| 42613432 | Immunotherapeutic targeting of calreticulin mutant myeloproliferative neoplasms. | Leukemia | 2026 | https://conductscience.org/library/papers/42613432 | PubMed |
| 42545540 | Calreticulin as a stress-responsive integrator of ER proteostasis, calcium homeostasis, and immune clearance. | Mol Biol Rep | 2026 | https://conductscience.org/library/papers/42545540 | PubMed |
| 42346284 | Frequency of Non-Type I/II CALR Mutations in Patients Undergoing Molecular Diagnostics for Myeloproliferative Neoplasms. | Diseases | 2026 | https://conductscience.org/library/papers/42346284 | PubMed |
| 42230475 | Genomic insights transform diagnosis, prognosis, and therapy in BCR::ABL1-negative myeloproliferative neoplasms. | Int J Hematol | 2026 | https://conductscience.org/library/papers/42230475 | PubMed |
| 42131291 | CDK6 inactivation counteracts CALR-mutant-induced MPN evolution and sensitizes MPN stem cells to interferon-α treatment. | Hemasphere | 2026 | https://conductscience.org/library/papers/42131291 | PubMed |
| 41959476 | Targeting TPO/MPL Signaling to Mitigate JAK2V617F-driven Cardiac Microvascular Disease. | bioRxiv | 2026 | https://conductscience.org/library/papers/41959476 | PubMed |
| 41798678 | Mutant calreticulin-directed immunotherapies in myeloproliferative neoplasms. | Blood Neoplasia | 2026 | https://conductscience.org/library/papers/41798678 | PubMed |
| 41532194 | A Murine Bispecific Antibody Efficiently Redirects T Cells Against Calr Mutated Stem Cells In Vivo. | Am J Hematol | 2026 | https://conductscience.org/library/papers/41532194 | PubMed |
| 41228192 | Challenges in the Evolving Role of Calreticulin as a Promising Target for Precision Medicine in Myeloproliferative Neoplasms. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/41228192 | PubMed |
| 41195513 | Loss of KDEL function from a calreticulin frameshift mutation drives expression of an immature, mutant calreticulin-dependent form of the thrombopoietin receptor MPL. | Haematologica | 2026 | https://conductscience.org/library/papers/41195513 | PubMed |
| 41087184 | [The role of AKT inhibitors combined with Ruxolitinib in ameliorating myeloproliferative disorders in mice with CALR gene mutations]. | Zhonghua Xue Ye Xue Za Zhi | 2025 | https://conductscience.org/library/papers/41087184 | PubMed |
| 40857671 | Novel strategies targeting mutant calreticulin in essential thrombocythemia and myelofibrosis. | Blood | 2026 | https://conductscience.org/library/papers/40857671 | PubMed |
Genes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CALR | 811 | PubTator's text mining | https://conductscience.org/library/genes/811 | NCBI Gene |
| JAK2 | 3717 | PubTator's text mining | https://conductscience.org/library/genes/3717 | NCBI Gene |
| MPL | 4352 | PubTator's text mining | https://conductscience.org/library/genes/4352 | NCBI Gene |
| THPO | 7066 | PubTator's text mining | https://conductscience.org/library/genes/7066 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/26817954
GET https://conductscience.org/api/papers/v1/26817954/cited_by?page=2